109814
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
淫羊藿苷通过 TP53 介导的铁死亡抑制肺腺癌进展
Authors Jin Q, OuYang L, Li J, Yang X, Guo L
Received 10 May 2025
Accepted for publication 26 October 2025
Published 15 November 2025 Volume 2025:18 Pages 1281—1298
DOI https://doi.org/10.2147/OTT.S539483
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Qihua Jin,1,2 Li OuYang,2 Jingjing Li,2 Xiaoxia Yang,3 Lihua Guo1,3
1The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People’s Republic of China; 2Department of TCM Respiratory, Yunnan Provincial Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, People’s Republic of China; 3Department of TCM Oncology, Yunnan Provincial Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, People’s Republic of China
Correspondence: Lihua Guo, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People’s Republic of China, Email guolihua1101@qq.com
Purpose: Lung adenocarcinoma (LUAD) represents the predominant histological subtype of non-small cell lung cancer (NSCLC) and is linked to a diminished overall survival (OS) rate. Icariin (ICA), the principal bioactive compound found in the medicinal plant Epimedium, has demonstrated significant efficacy in inhibiting tumor progression. Ferroptosis, an emerging mechanism of cellular demise, offers a promising avenue for therapeutic intervention in oncology. Nonetheless, the function and modulation of ferroptosis in LUAD are still significantly under-investigated.
Methods: A potential ferroptosis target was identified via bioinformatics analysis. Levels of reactive oxygen species (ROS) and ferroptosis-associated markers were quantified, while MTT, wound healing (WH), and Transwell assays were conducted to assess the effect of ICA on the malignant behavior of the LUAD cell line A549. The antitumor activity of ICA was further validated in vivo. Additionally, transcriptome sequencing and bioinformatics analysis were performed to explore ICA-induced molecular regulatory changes associated with the malignant phenotype of tumors.
Results: Bioinformatics analysis revealed that TP53 is a potential target of ferroptosis. Cellular experiments demonstrated that ICA induces ferroptosis in a dose-dependent manner, significantly reducing the proliferation, migration, and invasion abilities of A549 cells. Furthermore, the ferroptosis inhibitor Fer-1 can partially reverse both the ferroptosis and the increased expression of TP53 induced by ICA, indicating that ICA suppresses the malignant behavior of A549 cells by inducing TP53-mediated ferroptosis. This mechanism of action was further validated by in vivo experiments. Additional transcriptome sequencing and bioinformatics analysis showed that the mechanism by which ICA inhibits the proliferation of lung cancer cells may be related to its effects on cell cycle and metastasis-related gene sets, lipid metabolism, tumor immune microenvironment, and tumor-promoting pathways, including cholesterol metabolism, cortisol synthesis and secretion, and the PI3K-Akt signaling pathway.
Conclusion: ICA demonstrates antitumor properties in LUAD via TP53-mediated ferroptosis, consequently suppressing cellular proliferation.
Keywords: lung adenocarcinoma, icariin, ferroptosis, TP53, immune cell
1The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People’s Republic of China; 2Department of TCM Respiratory, Yunnan Provincial Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, People’s Republic of China; 3Department of TCM Oncology, Yunnan Provincial Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, People’s Republic of China
Correspondence: Lihua Guo, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People’s Republic of China, Email guolihua1101@qq.com
Purpose: Lung adenocarcinoma (LUAD) represents the predominant histological subtype of non-small cell lung cancer (NSCLC) and is linked to a diminished overall survival (OS) rate. Icariin (ICA), the principal bioactive compound found in the medicinal plant Epimedium, has demonstrated significant efficacy in inhibiting tumor progression. Ferroptosis, an emerging mechanism of cellular demise, offers a promising avenue for therapeutic intervention in oncology. Nonetheless, the function and modulation of ferroptosis in LUAD are still significantly under-investigated.
Methods: A potential ferroptosis target was identified via bioinformatics analysis. Levels of reactive oxygen species (ROS) and ferroptosis-associated markers were quantified, while MTT, wound healing (WH), and Transwell assays were conducted to assess the effect of ICA on the malignant behavior of the LUAD cell line A549. The antitumor activity of ICA was further validated in vivo. Additionally, transcriptome sequencing and bioinformatics analysis were performed to explore ICA-induced molecular regulatory changes associated with the malignant phenotype of tumors.
Results: Bioinformatics analysis revealed that TP53 is a potential target of ferroptosis. Cellular experiments demonstrated that ICA induces ferroptosis in a dose-dependent manner, significantly reducing the proliferation, migration, and invasion abilities of A549 cells. Furthermore, the ferroptosis inhibitor Fer-1 can partially reverse both the ferroptosis and the increased expression of TP53 induced by ICA, indicating that ICA suppresses the malignant behavior of A549 cells by inducing TP53-mediated ferroptosis. This mechanism of action was further validated by in vivo experiments. Additional transcriptome sequencing and bioinformatics analysis showed that the mechanism by which ICA inhibits the proliferation of lung cancer cells may be related to its effects on cell cycle and metastasis-related gene sets, lipid metabolism, tumor immune microenvironment, and tumor-promoting pathways, including cholesterol metabolism, cortisol synthesis and secretion, and the PI3K-Akt signaling pathway.
Conclusion: ICA demonstrates antitumor properties in LUAD via TP53-mediated ferroptosis, consequently suppressing cellular proliferation.
Keywords: lung adenocarcinoma, icariin, ferroptosis, TP53, immune cell